Version Control - Department of Health
Application 1483:Trabecular bypass micro-invasive glaucoma surgery (MIGS) device implantation in patients with mild-to-moderate primary open-angle glaucomaPICO Confirmation(to guide a new application to MSAC)(Version 0.1)This PICO Confirmation Template is to be completed to guide a new request for public funding for new or amended medical service(s) (including, but not limited to the Medicare Benefits Schedule (MBS)). It is relevant to proposals for both therapeutic and investigative medical services. Please complete all questions that are applicable to the proposed service, providing relevant information only. Should you require any further assistance, departmental staff are available through the Health Technology Assessment (HTA Team) on the contact number and email below to discuss the application form, or any other component of the Medical Services Advisory Committee process.Phone: +61 2 6289 7550Email: hta@.auWebsite: ControlDocument HistoryVersion NumberDate ChangedAuthorReason for Change0.110 March 2016Bianca LedbrookFinal template for publication1.03 April 2017Adelaide Health Technology AssessmentDraft PICO Confirmation for discussion at PASC2.019 May 2017Adelaide Health Technology AssessmentEdits to PICO Confirmation, based on ratified PASC outcomesDocument ApprovalVersion NumberDate ChangedAuthorReason for Change0.12016Template released for publication 2.01 June 2017PICO Confirmation ratified by PASC ChairSummary of PICO criteria to define the questions to be addressed in an Assessment Report to the Medical Services Advisory Committee (MSAC)Population 1ComponentDescriptionPatientsPatients with primary open-angle glaucoma (POAG) who have a current cataract co-morbidity and are receiving topical hypotensive drugs to lower intraocular pressure (IOP)InterventionCataract surgery with concurrent trabecular bypass micro-invasive glaucoma surgery (MIGS) stent implantation with/without additional medicationComparatorsCataract surgery plus medical management with topical hypotensive drugsCataract surgery with concurrent suprachoroidal MIGS stent implantation with/without additional medicationCataract surgery with concurrent trabecular bypass MIGS using different stents with/without additional medicationOutcomesClinical Effectiveness: Rate of vision impairment/loss, proportion of vision impairment/loss, time to vision impairment/loss, mean IOP reduction from baseline, proportion of patients with IOP reduction ≥ 20%, proportion of patients with IOP ≤ 18 mmHg, time to increase in IOP, change in the number of ocular hypotensive medications, proportion of patients on medication quality of life (effect on daily living activities, e.g. driving, walking, and reading), health-related quality of life (psychological burden due to fear of blindness, social withdrawal, and depression).Safety: Intraoperative complications, post-operative ocular complications, secondary surgical interventions, corrected distance visual acuity, visual field mean deviationCost-effectiveness: Cost, cost per quality adjusted life year or disability adjusted life year, incremental cost-effectiveness ratioAustralian Government healthcare costsResearch questionsWhat is the safety, effectiveness, and cost-effectiveness of cataract surgery with concurrent trabecular bypass MIGS stent implantation with/without additional medication compared with cataract surgery plus medical management with topical hypotensive drugs in patients with POAG who have a cataract co-morbidity?What is the safety, effectiveness, and cost-effectiveness of trabecular bypass MIGS stent implantation compared with suprachoroidal MIGS stent implantation in patients with POAG who are undergoing concurrent cataract surgery for a cataract co-morbidity?What is the comparative safety, effectiveness, and cost-effectiveness of different trabecular bypass MIGS stents in patients with POAG who are undergoing concurrent cataract surgery for a cataract co-morbidity?The PICO criteria for populations 2 and 3, as amended by PASC (based on applicant comments), are shown in the next two tables. If the applicant considers that populations 2 and 3 should be combined, the submission will need to be explicit regarding whether laser trabeculoplasty becomes a prior-intervention, or a comparator. Population 2ComponentDescriptionPatientsPatients with primary open-angle glaucoma (POAG) who have previously undergone cataract surgery and in whom medical management with topical hypotensive drugs alone is either no longer effective or not toleratedInterventionTrabecular bypass micro-invasive glaucoma surgery (MIGS) stent implantationComparatorLaser trabeculoplastySuprachoroidal MIGS stent implantationDifferent trabecular bypass MIGS stentsOutcomesClinical Effectiveness: Rate of vision impairment/loss, proportion of vision impairment/loss, time to vision impairment/loss, mean IOP reduction from baseline, proportion of patients with IOP reduction ≥ 20%, proportion of patients with IOP ≤ 18 mmHg, time to increase in IOP, change in the number of ocular hypotensive medications, proportion of patients on medication quality of life (effect on daily living activities, e.g. driving, walking, and reading), health-related quality of life (psychological burden due to fear of blindness, social withdrawal, and depression)Safety: Intraoperative complications, post-operative ocular complications, secondary surgical interventions, corrected distance visual acuity, visual field mean deviationCost-effectiveness: Cost, cost per quality adjusted life year or disability adjusted life year, incremental cost-effectiveness ratioAustralian Government healthcare costsResearch questionsWhat is the safety, effectiveness, and cost-effectiveness of trabecular bypass MIGS stent implantation compared with laser trabeculoplasty in patients with POAG who have previously undergone cataract surgery?What is the safety, effectiveness, and cost-effectiveness of trabecular bypass MIGS stent implantation compared with suprachoroidal MIGS stent implantation in patients with POAG who have previously undergone cataract surgery?What is the comparative safety, effectiveness, and cost-effectiveness of different trabecular bypass MIGS stents in patients with POAG who have previously undergone cataract surgery?Population 3ComponentDescriptionPatientsPatients with primary open-angle glaucoma (POAG) who have no history of cataracts and in whom laser trabeculoplasty has either failed or is unlikely to be successful InterventionTrabecular bypass micro-invasive glaucoma surgery (MIGS) stent implantationComparatorTrabeculectomyOther incisional surgical proceduresSuprachoroidal MIGS stent implantationDifferent trabecular bypass MIGS stentsOutcomesClinical Effectiveness: Rate of vision impairment/loss, proportion of vision impairment/loss, time to vision impairment/loss, mean IOP reduction from baseline, proportion of patients with IOP reduction ≥ 20%, proportion of patients with IOP ≤ 18 mmHg, time to increase in IOP, change in the number of ocular hypotensive medications, proportion of patients on medication quality of life (effect on daily living activities, e.g. driving, walking, and reading), health-related quality of life (psychological burden due to fear of blindness, social withdrawal, and depression)Safety: Intraoperative complications, post-operative ocular complications, secondary surgical interventions, corrected distance visual acuity, visual field mean deviationCost-effectiveness: Cost, cost per quality adjusted life year or disability adjusted life year, incremental cost-effectiveness ratioAustralian Government healthcare costsResearch questionsWhat is the safety, effectiveness, and cost-effectiveness of trabecular bypass MIGS stent implantation compared trabeculectomy or other incisional surgical procedures in patients with POAG who have no history of cataracts?What is the safety, effectiveness, and cost-effectiveness of trabecular bypass MIGS stent implantation compared suprachoroidal MIGS stent implantation in patients with POAG who have no history of cataracts?What is the comparative safety, effectiveness, and cost-effectiveness of different trabecular bypass MIGS stents in patients with POAG who have no history of cataracts?PICO rationale for therapeutic and investigative medical services onlyPopulationGlaucoma is a chronic, degenerative optic neuropathy characterised by progressive vision loss due to the loss of retinal ganglion cells and optic nerve damage PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ld29uPC9BdXRob3I+PFllYXI+MjAwOTwvWWVhcj48UmVj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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Ld29uPC9BdXRob3I+PFllYXI+MjAwOTwvWWVhcj48UmVj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ADDIN EN.CITE.DATA (Kwon et al. 2009; Quigley 2011). It is the number one cause of irreversible vision loss and the second leading cause of blindness worldwide ADDIN EN.CITE <EndNote><Cite><Author>Conlon</Author><Year>2017</Year><RecNum>1072</RecNum><DisplayText>(Conlon, Saheb & Ahmed 2017)</DisplayText><record><rec-number>1072</rec-number><foreign-keys><key app="EN" db-id="wsvssztxiw0dsbeat085zeafe2aa0w0psvpt" timestamp="1488776401">1072</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Conlon, R.</author><author>Saheb, H.</author><author>Ahmed,, II</author></authors></contributors><auth-address>University of Ottawa, Ottawa, Ont.
McGill University, Montreal, Que.. Electronic address: hady.saheb@mcgill.ca.
University of Toronto, Toronto, Ont.; Trillium Health Partners, Mississauga, Ont.; Prism Eye Institute, Mississauga, Ont.</auth-address><titles><title>Glaucoma treatment trends: a review</title><secondary-title>Can J Ophthalmol</secondary-title></titles><periodical><full-title>Can J Ophthalmol</full-title></periodical><pages>114-124</pages><volume>52</volume><number>1</number><edition>2017/02/27</edition><dates><year>2017</year><pub-dates><date>Feb</date></pub-dates></dates><isbn>1715-3360 (Electronic)
0008-4182 (Linking)</isbn><accession-num>28237137</accession-num><urls><related-urls><url>;(Conlon, Saheb & Ahmed 2017). Peters et al. PEVuZE5vdGU+PENpdGUgRXhjbHVkZUF1dGg9IjEiPjxBdXRob3I+UGV0ZXJzPC9BdXRob3I+PFll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ADDIN EN.CITE PEVuZE5vdGU+PENpdGUgRXhjbHVkZUF1dGg9IjEiPjxBdXRob3I+UGV0ZXJzPC9BdXRob3I+PFll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ADDIN EN.CITE.DATA (2013) reported that the risk of blindness in at least 1 eye and bilateral blindness from glaucoma were 26.5% and 5.5%, respectively, after 10 years, and 38.1% and 13.5% at 20 years.An increase in intraocular pressure (IOP) is thought to be a major cause of glaucoma. IOP increases either when too much aqueous humour fluid is produced or when aqueous humour outflow is decreased. There are two outflow pathways, for a diagram of the structure of the eye showing these pathways, see footnote below. In the trabecual pathway, the trabecular meshwork is responsible for draining the aqueous humour from the anterior chamber. It is a spongy tissue located around the base of the cornea, between Schlemm's canal and the anterior chamber. The trabecular meshwork drains the aqueous humour into Schlemm's canal, which is a circular lymphatic-like vessel that delivers the collected the aqueous humour into the episcleral blood vessels. The uveo-scleral pathway starts with the aqueous humour filtering between the muscle bundles of the ciliary body; with this being the rate-limiting step. The aqueous humour flows into the suprachoroidal space, through the sclera and into the lymphatics to be drained away from the eye.Glaucoma is referred to as open-angle or closed-angle depending on whether the drainage channels for aqueous humour in the front of the eye appear open or closed PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Cb2xhbmQ8L0F1dGhvcj48WWVhcj4yMDEzPC9ZZWFyPjxS
ZWNOdW0+MTA4MDwvUmVjTnVtPjxEaXNwbGF5VGV4dD4oQm9sYW5kIGV0IGFsLiAyMDEzKTwvRGlz
cGxheVRleHQ+PHJlY29yZD48cmVjLW51bWJlcj4xMDgwPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtl
eXM+PGtleSBhcHA9IkVOIiBkYi1pZD0id3N2c3N6dHhpdzBkc2JlYXQwODV6ZWFmZTJhYTB3MHBz
dnB0IiB0aW1lc3RhbXA9IjE0ODg3NzkyMjkiPjEwODA8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVm
LXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48
YXV0aG9ycz48YXV0aG9yPkJvbGFuZCwgTS4gVi48L2F1dGhvcj48YXV0aG9yPkVydmluLCBBLiBN
LjwvYXV0aG9yPjxhdXRob3I+RnJpZWRtYW4sIEQuIFMuPC9hdXRob3I+PGF1dGhvcj5KYW1wZWws
IEguIEQuPC9hdXRob3I+PGF1dGhvcj5IYXdraW5zLCBCLiBTLjwvYXV0aG9yPjxhdXRob3I+Vm9s
bGVud2VpZGVyLCBELjwvYXV0aG9yPjxhdXRob3I+Q2hlbGxhZHVyYWksIFkuPC9hdXRob3I+PGF1
dGhvcj5XYXJkLCBELjwvYXV0aG9yPjxhdXRob3I+U3VhcmV6LUN1ZXJ2bywgQy48L2F1dGhvcj48
YXV0aG9yPlJvYmluc29uLCBLLiBBLjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48
YXV0aC1hZGRyZXNzPkpvaG5zIEhvcGtpbnMgVW5pdmVyc2l0eSBTY2hvb2wgb2YgTWVkaWNpbmUs
IEJhbHRpbW9yZSwgTUQsIFVTQS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Db21wYXJh
dGl2ZSBlZmZlY3RpdmVuZXNzIG9mIHRyZWF0bWVudHMgZm9yIG9wZW4tYW5nbGUgZ2xhdWNvbWE6
IGEgc3lzdGVtYXRpYyByZXZpZXcgZm9yIHRoZSBVLlMuIFByZXZlbnRpdmUgU2VydmljZXMgVGFz
ayBGb3JjZTwvdGl0bGU+PHNlY29uZGFyeS10aXRsZT5Bbm4gSW50ZXJuIE1lZDwvc2Vjb25kYXJ5
LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkFubiBJbnRlcm4gTWVkPC9m
dWxsLXRpdGxlPjwvcGVyaW9kaWNhbD48cGFnZXM+MjcxLTk8L3BhZ2VzPjx2b2x1bWU+MTU4PC92
b2x1bWU+PG51bWJlcj40PC9udW1iZXI+PGVkaXRpb24+MjAxMy8wMi8yMDwvZWRpdGlvbj48a2V5
d29yZHM+PGtleXdvcmQ+Q29tcGFyYXRpdmUgRWZmZWN0aXZlbmVzcyBSZXNlYXJjaDwva2V5d29y
ZD48a2V5d29yZD5HbGF1Y29tYSwgT3Blbi1BbmdsZS9jb21wbGljYXRpb25zL3BoeXNpb3BhdGhv
bG9neS8gdGhlcmFweTwva2V5d29yZD48a2V5d29yZD5IdW1hbnM8L2tleXdvcmQ+PGtleXdvcmQ+
SW50cmFvY3VsYXIgUHJlc3N1cmUvZHJ1ZyBlZmZlY3RzPC9rZXl3b3JkPjxrZXl3b3JkPkxhc2Vy
IFRoZXJhcHk8L2tleXdvcmQ+PGtleXdvcmQ+T3B0aWMgTmVydmUvcGF0aG9sb2d5PC9rZXl3b3Jk
PjxrZXl3b3JkPlByb3N0YWdsYW5kaW5zL3RoZXJhcGV1dGljIHVzZTwva2V5d29yZD48a2V5d29y
ZD5SYW5kb21pemVkIENvbnRyb2xsZWQgVHJpYWxzIGFzIFRvcGljPC9rZXl3b3JkPjxrZXl3b3Jk
PlRyYWJlY3VsZWN0b215PC9rZXl3b3JkPjxrZXl3b3JkPlZpc2lvbiBEaXNvcmRlcnMvcHJldmVu
dGlvbiAmYW1wOyBjb250cm9sPC9rZXl3b3JkPjxrZXl3b3JkPlZpc3VhbCBGaWVsZHMvZHJ1ZyBl
ZmZlY3RzPC9rZXl3b3JkPjwva2V5d29yZHM+PGRhdGVzPjx5ZWFyPjIwMTM8L3llYXI+PHB1Yi1k
YXRlcz48ZGF0ZT5GZWIgMTk8L2RhdGU+PC9wdWItZGF0ZXM+PC9kYXRlcz48aXNibj4xNTM5LTM3
MDQgKEVsZWN0cm9uaWMpJiN4RDswMDAzLTQ4MTkgKExpbmtpbmcpPC9pc2JuPjxhY2Nlc3Npb24t
bnVtPjIzNDIwMjM1PC9hY2Nlc3Npb24tbnVtPjx1cmxzPjxyZWxhdGVkLXVybHM+PHVybD5odHRw
Oi8vYW5uYWxzLm9yZy9wZGZhY2Nlc3MuYXNoeD91cmw9L2RhdGEvam91cm5hbHMvYWltLzkyNjM4
Ny8wMDAwNjA1LTIwMTMwMjE5MC0wMDAwOC5wZGY8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+
PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEwLjczMjYvMDAwMy00ODE5LTE1OC00LTIwMTMwMjE5
MC0wMDAwODwvZWxlY3Ryb25pYy1yZXNvdXJjZS1udW0+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRl
cj5OTE08L3JlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48
L3JlY29yZD48L0NpdGU+PC9FbmROb3RlPgB=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Cb2xhbmQ8L0F1dGhvcj48WWVhcj4yMDEzPC9ZZWFyPjxS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ADDIN EN.CITE.DATA (Boland et al. 2013). In primary open angle glaucoma (POAG), the decreased outflow is attributed to increased resistance due to age-related thickening or sclerosis of the trabecular meshwork and absence of giant cells in Schlemm’s canal. POAG is the most common form and is triggered by both environmental and genetic risk factors; up to 50% of patients have a positive family history of POAG PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BbGxpbmdoYW08L0F1dGhvcj48WWVhcj4yMDA5PC9ZZWFy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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BbGxpbmdoYW08L0F1dGhvcj48WWVhcj4yMDA5PC9ZZWFy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ADDIN EN.CITE.DATA (Allingham, Liu & Rhee 2009; Janssen et al. 2013).A diagnosis of POAG is made only after the other types of glaucoma have been excluded and is based on a characteristic progressive enlargement of the optic cup (disc cupping) ADDIN EN.CITE <EndNote><Cite><Author>Foster</Author><Year>2002</Year><RecNum>1087</RecNum><DisplayText>(Foster et al. 2002; Leske 1983)</DisplayText><record><rec-number>1087</rec-number><foreign-keys><key app="EN" db-id="wsvssztxiw0dsbeat085zeafe2aa0w0psvpt" timestamp="1488867648">1087</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Foster, Paul J</author><author>Buhrmann, Ralf</author><author>Quigley, Harry A</author><author>Johnson, Gordon J</author></authors></contributors><titles><title>The definition and classification of glaucoma in prevalence surveys</title><secondary-title>British Journal of Ophthalmology</secondary-title></titles><periodical><full-title>British Journal of Ophthalmology</full-title></periodical><pages>238-242</pages><volume>86</volume><number>2</number><dates><year>2002</year></dates><urls><related-urls><url> app="EN" db-id="wsvssztxiw0dsbeat085zeafe2aa0w0psvpt" timestamp="1488865905">1086</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Leske, M. Cristina</author></authors></contributors><titles><title>The Epidemiology of Open-Angle Glaucoma: A Review</title><secondary-title>American Journal of Epidemiology</secondary-title></titles><periodical><full-title>American Journal of Epidemiology</full-title></periodical><pages>166-191</pages><volume>118</volume><number>2</number><dates><year>1983</year></dates><isbn>0002-9262</isbn><urls><related-urls><url>;(Foster et al. 2002; Leske 1983). The vertical cup:disc ratio is a simple, relatively robust index of glaucomatous loss of the neuroretinal rim. Vision field defects may not yet be detected in mild disease, but as the disease progresses visual field abnormalities become more apparent. High IOP >21 mmHg, is a major risk factor for both developing POAG and for progression to irreversible vision loss, however, 15–40% of patients with POAG have normal IOP ADDIN EN.CITE <EndNote><Cite><Author>Maier</Author><Year>2005</Year><RecNum>1085</RecNum><DisplayText>(Maier et al. 2005)</DisplayText><record><rec-number>1085</rec-number><foreign-keys><key app="EN" db-id="wsvssztxiw0dsbeat085zeafe2aa0w0psvpt" timestamp="1488843791">1085</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Maier, P. C.</author><author>Funk, J.</author><author>Schwarzer, G.</author><author>Antes, G.</author><author>Falck-Ytter, Y. T.</author></authors></contributors><auth-address>Department of Ophthalmology, University Hospital Freiburg, Killianstr 5, D-79106 Freiburg, Germany. maierphi@aug.ukl.uni-freiburg.de</auth-address><titles><title>Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials</title><secondary-title>BMJ</secondary-title></titles><periodical><full-title>BMJ</full-title></periodical><pages>134</pages><volume>331</volume><number>7509</number><edition>2005/07/05</edition><keywords><keyword>Glaucoma, Open-Angle/complications/ therapy</keyword><keyword>Humans</keyword><keyword>Ocular Hypertension/complications/ therapy</keyword><keyword>Proportional Hazards Models</keyword><keyword>Randomized Controlled Trials as Topic</keyword><keyword>Risk Factors</keyword></keywords><dates><year>2005</year><pub-dates><date>Jul 16</date></pub-dates></dates><isbn>1756-1833 (Electronic)
0959-535X (Linking)</isbn><accession-num>15994659</accession-num><urls><related-urls><url>;(Maier et al. 2005).Patients with confirmed POAG expected to access trabecular bypass micro-invasive glaucoma surgery (MIGS) stent implantation through the Medicare Benefits Schedule (MBS) can be broadly divided into two groups:Patients who will undergo implantation in conjunction with cataract surgery (population 1). MIGS stent implantation would be considered earlier in the management pathway for these patients (depending on the need for cataract surgery), and would be an adjunct to topical hypotensive medication;Patients who will receive the intervention as a stand-alone procedure. These patients can be further divided in two sub-groups:patients who have previously undergone cataract surgery (referred to as pseudophakic) and who are currently unable to maintain target IOP with maximally tolerated topical hypotensive medication (population 2); and patients who do not exhibit any signs of cataract development (referred to as phakic) in whom conventional medication management and less invasive interventional techniques (i.e. laser trabeculoplasty) have not been successful (population 3).As patients from populations 2 and 3 comprise less than 5% of all patients having a MIGS implantation procedure, the applicant proposed that populations 2 and 3 be combined and defined as: Patients who will receive the intervention as a stand-alone procedure (population 2). In clinical practice, MIGS will be positioned where conservative therapies have failed, are likely to have failed, or are contraindicated. In this population MIGS stent implantation would supplant or delay other incisional surgeries, such as trabeculectomy (population 2).The PICO Advisory Sub-Committee (PASC) considered this was a reasonable approach (i.e. an assessment in which populations 2 and 3 have been combined), given the paucity of evidence for these patients. The submission will need to define ‘conservative therapies’, to be explicit regarding whether this includes laser trabeculoplasty or not. If it does, then the implication of combining the populations will be that MIGS stent implantation for population 2 will be later in the pathway (after laser trabeculoplasty, rather than an alternate to laser trabeculoplasty). If ‘conservative therapies’ excludes laser trabeculoplasty, then population 3 will be expanded to allow earlier treatment (i.e. laser trabeculoplasty becomes a comparator, rather than required prior-treatment).Prevalence of POAG and cataracts among adults in AustraliaGlaucoma affects approximately 66.8 million people worldwide, and up to 50% of people in the industrialised world are unaware of their condition and are therefore not receiving appropriate treatment ADDIN EN.CITE <EndNote><Cite><Author>Conlon</Author><Year>2017</Year><RecNum>1072</RecNum><DisplayText>(Conlon, Saheb & Ahmed 2017)</DisplayText><record><rec-number>1072</rec-number><foreign-keys><key app="EN" db-id="wsvssztxiw0dsbeat085zeafe2aa0w0psvpt" timestamp="1488776401">1072</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Conlon, R.</author><author>Saheb, H.</author><author>Ahmed,, II</author></authors></contributors><auth-address>University of Ottawa, Ottawa, Ont.
McGill University, Montreal, Que.. Electronic address: hady.saheb@mcgill.ca.
University of Toronto, Toronto, Ont.; Trillium Health Partners, Mississauga, Ont.; Prism Eye Institute, Mississauga, Ont.</auth-address><titles><title>Glaucoma treatment trends: a review</title><secondary-title>Can J Ophthalmol</secondary-title></titles><periodical><full-title>Can J Ophthalmol</full-title></periodical><pages>114-124</pages><volume>52</volume><number>1</number><edition>2017/02/27</edition><dates><year>2017</year><pub-dates><date>Feb</date></pub-dates></dates><isbn>1715-3360 (Electronic)
0008-4182 (Linking)</isbn><accession-num>28237137</accession-num><urls><related-urls><url>;(Conlon, Saheb & Ahmed 2017). In 2004, it was estimated that between 2.7% and 3.7% of Australians aged 55 years or more had glaucoma. There was no significant difference in prevalence rates between men and women.Although glaucoma and cataracts are not related conditions, co-morbidity will occur in many patients. This is likely due to the large number of older people with cataracts. Approximately 31% of Australians aged 55 or more suffer from cataracts. Age-specific rates for cataracts are well over 70% for both men and women aged 80 or more.RationaleThere are five randomised controlled trials (RCTs) investigating the effectiveness of combined trabecular bypass MIGS and cataract surgery listed in the summary of evidence. Patients enrolled in these trials all had a diagnosis of POAG with mild to moderate disease (cup:disc ratio of ≤0.8) and an elevated IOP (un-medicated IOP >18 and ≤36 mmHg). Thus, the population in the evidence base matches population 1.There are also three RCTs investigating the effectiveness of trabecular bypass MIGS as a stand-alone procedure. All three trials excluded patients with cataracts and one PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Wb2xkPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48UmVj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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Wb2xkPC9BdXRob3I+PFllYXI+MjAxNjwvWWVhcj48UmVj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ADDIN EN.CITE.DATA (Vold et al. 2016) also excluded patients with prior cataract surgery. In the other two trials only 2% ADDIN EN.CITE <EndNote><Cite><Author>Katz</Author><Year>2015</Year><RecNum>431</RecNum><DisplayText>(Katz et al. 2015)</DisplayText><record><rec-number>431</rec-number><foreign-keys><key app="EN" db-id="wsvssztxiw0dsbeat085zeafe2aa0w0psvpt" timestamp="1488514166">431</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Katz, L. J.</author><author>Erb, C.</author><author>Carceller, G. A.</author><author>Fea, A. M.</author><author>Voskanyan, L.</author><author>Wells, J. M.</author><author>Giamporcaro, J. E.</author></authors></contributors><auth-address>Wills Eye Hospital, Jefferson Medical College, Philadelphia, PA, USA.
Eye Clinic Wittenbergplatz, Berlin, Germany.
Department of Ophthalmology, Hospital d'Hebron, Barcelona, Spain.
University Eye Clinic of the University of Turin, Turin, Italy.
SV Malayan Opthalmology Centre, Yerevan, Armenia.
Glaukos Corporation, Laguna Hills, CA, USA.</auth-address><titles><title>Prospective, randomized study of one, two, or three trabecular bypass stents in open-angle glaucoma subjects on topical hypotensive medication</title><secondary-title>Clin Ophthalmol</secondary-title></titles><periodical><full-title>Clin Ophthalmol</full-title></periodical><pages>2313-20</pages><volume>9</volume><edition>2015/12/31</edition><keywords><keyword>IOP reduction</keyword><keyword>Migs</keyword><keyword>Oag</keyword><keyword>iStent</keyword><keyword>intraocular pressure</keyword><keyword>multiple stents</keyword></keywords><dates><year>2015</year></dates><isbn>1177-5467 (Print)
1177-5467 (Linking)</isbn><accession-num>26715834</accession-num><urls><related-urls><url>;(Katz et al. 2015) and 3% PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GZWE8L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFyPjxSZWNO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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GZWE8L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFyPjxSZWNO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ADDIN EN.CITE.DATA (Fea et al. 2014) of patients had had previous cataract surgery. Patients in these trials most closely match population 3, which suggests there may be little evidence to support the use of trabecular bypass MIGS in population 2. The phakic patients enrolled in 2 of the studies were using either one PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GZWE8L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFyPjxSZWNO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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GZWE8L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFyPjxSZWNO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ADDIN EN.CITE.DATA (Fea et al. 2014) or two ADDIN EN.CITE <EndNote><Cite><Author>Katz</Author><Year>2015</Year><RecNum>431</RecNum><DisplayText>(Katz et al. 2015)</DisplayText><record><rec-number>431</rec-number><foreign-keys><key app="EN" db-id="wsvssztxiw0dsbeat085zeafe2aa0w0psvpt" timestamp="1488514166">431</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Katz, L. J.</author><author>Erb, C.</author><author>Carceller, G. A.</author><author>Fea, A. M.</author><author>Voskanyan, L.</author><author>Wells, J. M.</author><author>Giamporcaro, J. E.</author></authors></contributors><auth-address>Wills Eye Hospital, Jefferson Medical College, Philadelphia, PA, USA.
Eye Clinic Wittenbergplatz, Berlin, Germany.
Department of Ophthalmology, Hospital d'Hebron, Barcelona, Spain.
University Eye Clinic of the University of Turin, Turin, Italy.
SV Malayan Opthalmology Centre, Yerevan, Armenia.
Glaukos Corporation, Laguna Hills, CA, USA.</auth-address><titles><title>Prospective, randomized study of one, two, or three trabecular bypass stents in open-angle glaucoma subjects on topical hypotensive medication</title><secondary-title>Clin Ophthalmol</secondary-title></titles><periodical><full-title>Clin Ophthalmol</full-title></periodical><pages>2313-20</pages><volume>9</volume><edition>2015/12/31</edition><keywords><keyword>IOP reduction</keyword><keyword>Migs</keyword><keyword>Oag</keyword><keyword>iStent</keyword><keyword>intraocular pressure</keyword><keyword>multiple stents</keyword></keywords><dates><year>2015</year></dates><isbn>1177-5467 (Print)
1177-5467 (Linking)</isbn><accession-num>26715834</accession-num><urls><related-urls><url>;(Katz et al. 2015) medications and required additional IOP lowering to control their OAG. In the study by Vold et al PEVuZE5vdGU+PENpdGUgRXhjbHVkZUF1dGg9IjEiPjxBdXRob3I+Vm9sZDwvQXV0aG9yPjxZZWFy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ADDIN EN.CITE PEVuZE5vdGU+PENpdGUgRXhjbHVkZUF1dGg9IjEiPjxBdXRob3I+Vm9sZDwvQXV0aG9yPjxZZWFy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ADDIN EN.CITE.DATA (2016) the patients were newly diagnosed with POAG and had not undergone any treatment. Although there is evidence for phakic patients who have mild to moderate disease (cup:disc ratio of ≤0.9), they have milder IOP control problems than the population specified in the application. These patients did not receive previous invasive interventional techniques, such as laser trabeculoplasty, and therefore would not be eligible for trabecular bypass MIGS, based on the clinical pathway provided by the applicant for population 3. InterventionTrabecular bypass MIGS stent implantation procedures involve a minimally invasive micro-incision approach (usually into the cornea), to minimize tissue scarring, and allow for the possibility of other glaucoma procedures such as trabeculectomy or aqueous/tube stent implantation to be performed in the future if needed PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Hb25uZXJtYW5uPC9BdXRob3I+PFllYXI+MjAxNzwvWWVh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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Hb25uZXJtYW5uPC9BdXRob3I+PFllYXI+MjAxNzwvWWVh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ADDIN EN.CITE.DATA (Gonnermann et al. 2017).The proposed service involves the delivery of a trabecular bypass stent – pre-loaded on an inserter specific to each device – into the trabecular meshwork of the eye. The implantation of the stent(s) ab interno (from inside the eye), via a corneal incision, is guided by gonioscopy. The exact positioning within the anterior structures (trabecular meshwork and Schlemm’s canal) are specific to each device. However, the complexity and resource intensity of the implantation procedure is comparable regardless of trabecular bypass stent implanted (iStent or Hydrus). The applicant has indicated that the procedure requires approximately 30-60 minutes of operating and preparation time as a stand-alone procedure. A response to the targeted consultation survey on MSAC application 1483 indicated it would take approximately 15 minutes of a surgeon’s time and significantly less than 15 minutes if combined with cataract surgery. The applicant advised that fifteen minutes is considered the minimum amount of professional time required when the stent implantation procedure is performed in conjunction with cataract surgery, and overall procedural time for an experienced surgeon does not significantly differ between devices. PASC considered that, if the length of time did not vary for cataract removal (with or without MIGS), further justification of the MBS fee will need to be provided during the assessment phase. PASC noted that goniotomy is traditionally performed in a paediatric patient population for congenital glaucoma, and this application expands that population to an older patient group.Three stent devices are relevant to trabecular bypass MIGS in the treatment of patients with mild-to-moderate POAG, with or without cataracts: the iStent, the iStent inject system, and the Hydrus Miscrostent.The iStent Trabecular Micro-Bypass Stent is an L-shaped heparin-coated titanium device, 0.33 mm in height and 1.00 mm in length, with a snorkel length of 0.25 mm PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OZXVoYW5uPC9BdXRob3I+PFllYXI+MjAxNTwvWWVhcj48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==
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OZXVoYW5uPC9BdXRob3I+PFllYXI+MjAxNTwvWWVhcj48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==
ADDIN EN.CITE.DATA (Neuhann 2015). The iStent is preloaded into a disposable inserter to enable accurate insertion of the device into the Schlemm’s canal PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OZXVoYW5uPC9BdXRob3I+PFllYXI+MjAxNTwvWWVhcj48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==
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5OZXVoYW5uPC9BdXRob3I+PFllYXI+MjAxNTwvWWVhcj48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==
ADDIN EN.CITE.DATA (Neuhann 2015). The surgeon positions the iStent inserter through a corneal incision using gonioscopy to guide the stent through the trabecular meshwork and into Schlemm’s canal in the nasal portion of the aqueous drainage system. Once implanted, the stent body is in the Schlemm’s canal with the snorkel protruding into in the anterior chamber PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HYWxsYXJkbzwvQXV0aG9yPjxZZWFyPjIwMTY8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5HYWxsYXJkbzwvQXV0aG9yPjxZZWFyPjIwMTY8L1llYXI+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ADDIN EN.CITE.DATA (Gallardo et al. 2016). This creates a conduit for aqueous humour drainage from the anterior chamber into Schlemm’s canal.The iStent inject system is a second-generation heparin-coated titanium device, which provides the ability to house two stents in the trabecular meshwork to increase outflow while entering the eye only once. Under gonioscopic view, the injector is positioned such that two iStents are implanted through the trabecular meshwork into the nasal Schlemm’s canal, separated by approximately sixty degrees PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Hb25uZXJtYW5uPC9BdXRob3I+PFllYXI+MjAxNzwvWWVh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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5Hb25uZXJtYW5uPC9BdXRob3I+PFllYXI+MjAxNzwvWWVh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ADDIN EN.CITE.DATA (Gonnermann et al. 2017; Lindstrom et al. 2016).PASC considered that clarification is needed on use of two stents (rather than one) in clinical practice, as this will have Prostheses List benefit implications (especially given the iStent inject system is more expensive than the single iStent device, and inclusion of the criteria that define the circumstances under which the more expensive stent would be used).The applicant advised that use of two stents produces superior outcomes to the single stent procedure (i.e. one iStent results in a 6 mm Hg reduction in IOP, while two stents (iStent inject) results in a 14–16 mmHg reduction). The applicant advised that, for every 1 mmHg reduction, there is a 10% reduction in disease progression.Both the iStent Trabecular Micro-Bypass Stent and the iStent inject system have Therapeutic Goods Administration (TGA) approval for use in conjunction with cataract surgery in subjects with mild to moderate OAG currently treated with ocular hypotensive medication. The sponsors are currently seeking an amendment for implantation with or without concomitant cataract surgery. The estimated date for the TGA decision is between May and July, this year.The Hydrus Microstent is the longest of the MIGS stent devices (8?mm long implant), and serves as an intra-canalicular scaffold once implanted into Schlemm’s canal. The delivery device makes a small incision through the trabecular meshwork and the inner wall of Schlemm’s canal. The microstent is then advanced along the canal, with 1-2mm of stent remaining in the anterior chamber. The stent mechanically dilates and holds open Schlemm’s canal. The length of the Hydrus Microstent is thought to open approximately one quarter of Schlemm’s canal, enabling the aqueous humour to flow into open downstream collector channels. The Hydrus Microstent has TGA approval for use in patients with POAG as a standalone treatment or in conjunction with cataract surgery.Trabecular bypass MIGS stent implantation has been performed in Australia for the last 2–3 years and has been funded under MBS item number 42758 (goniotomy). However, a Medicare Benefits Schedule (MBS) review has determined that item 42758 does not cover the implantation of trabecular bypass MIGS stents and an amendment explicitly excluding this procedure will be added to this item number, effective 1 May 2017. The applicant confirmed that trabecular bypass MIGS stent implantation is likely to be performed only once per eye (maximum of two procedures per person). However, the patient may need repositioning or removal of the stent at a later date.The applicant also stated there are limitations with the procedure, being that it is ineffective for complete obstruction of trabecular meshwork.RationaleMIGS stent implantation in patients with POAG is intended to reduce the medication burden for patients while maintaining IOP at a target level. This may be achieved by either directly reducing the number of hypotensive medications required per day (on average one less medication is required), or avoiding the need for an increase in medication over time. Following insertion of a stent, 80% of patients no longer need topical medication.Cataract surgery is common among patients with POAG, especially those aged 55 years or older. Thus, MIGS stent implantation will take place at the same time as the cataract surgery in approximately 20% of patients with cataracts (population 1), because addressing these two conditions in a single operation minimises the risk of surgery-related complications (i.e. infection). In pseudophakic patients who have had previous cataract surgery and in whom medical management with topical hypotensive drugs alone is either no longer effective or not tolerated (population 2) MIGS stent implantation would occur as a stand-alone procedure instead of laser trabeculoplasty. In these patients there is no likelihood of damaging the lens, thus MIGS can occur earlier in the progression of glaucoma than in phakic patients with no history of cataracts who still have their natural lens (population 3). In patients with a natural lens there is less space in the eye, and there is a risk of damaging the lens; therefore, MIGS stent implantation is delayed until laser trabeculoplasty has failed (or is unlikely to be successful) and is performed instead of a trabeculectomy.The potential for MIGS to be performed prophylactically in patients requiring cataract surgery should be addressed in the paratorsThere are three different types of comparators to trabecular bypass MIGS stent implantation: the comparators that would be considered in the absence of MIGS stent implantation, a comparison with an alternative form of MIGS stent implantation using a suprachoroidal micro-stent, and a comparison between the three different trabecular bypass MIGS stents. Suprachoroidal MIGS stent implantationThe CyPass suprachoroidal micro-stent is a polyimide tube with a fenestrated lumen. It is 6.35 mm long with an inner diameter of 0.30 mm and the outer diameter of 0.43 mm. The implantation of the stent ab interno, via a corneal incision, is guided by gonioscopy and placed in the angle of the eye, with the proximal end extending into the anterior chamber to allow outflow of aqueous fluid in the supraciliary and suprachoroidal space, where the distal end resides, via the uveoscleral pathway.Population 1: Patients with POAG and a current cataract co-morbidityIn patients who require cataract surgery, MIGS stent implantation would be considered early in the management algorithm, as an adjunctive treatment to topical hypotensive medication. The cataract and MIGS stent implantation would be performed together as one procedure. These patients would not yet be considered for laser trabeculoplasty in the current clinical algorithm. Thus, the only appropriate comparator to MIGS stent implantation for POAG patients with a cataract co-morbidity is cataract surgery with medical management of IOP with ocular hypotensive drugs. Topical hypotensive medication represents the first-line therapy for patients with POAG. Patients start with a single topical medication, and increase the dosing frequency and number of therapies, as required, in order to maintain a target IOP. There are four main classes of pharmacotherapy available through the Pharmaceutical Benefits Scheme (PBS) that are used to treat glaucoma in Australia: Prostaglandin analogues are the first choice for most newly diagnosed patients and are the most commonly prescribed hypotensive medications for glaucoma:Currently available on the PBS: bimatoprost, latanoprost, tafluprost and travoprost;Beta-blockers are the second most commonly prescribed class of topical glaucoma medications and are also used as first-line therapy for some patients:Currently available on the PBS: betaxolol and timolol;Alpha agonists and carbonic anhydrase inhibitors are commonly used as adjunctive therapy when IOP is inadequately controlled with one medication;Currently available on the PBS: brimonidine, apraclonidine, brinzolamide, dorzolamide;Fixed combination agents of the above classes are also available:Currently available on the PBS: Prostaglandin analogues bimatoprost, latanoprost and travoprost in combination with beta-blocker timolol;Alpha agonists and carbonic anhydrase inhibitors brimonidine, brinzolamide and dorzolamide in combination with beta-blocker timolol;Alpha agonist (brimonidine) in combination with a carbonic anhydrase (brinzolamide).Population 2: Patients with POAG who have previously undergone cataract surgeryUnder the proposed clinical pathway, patients who have had previous cataract surgery and are experiencing inadequate IOP control with maximal-tolerated hypotensive medication or due to poor compliance, or other treatment-related adverse events would be considered for MIGS stent implantation instead of laser trabeculoplasty. This is because these patients are not at risk of damage to the lens from MIGS. As the alternative treatment for these patients would be laser trabeculoplasty, this would be the correct comparator to MIGS stent implantation for these patients. Laser trabeculoplasty is reimbursed under MBS item numbers 42782 (up to 4 treatments in 2-year period) and 42783 (5th or subsequent treatment in 2-year period).There are two main types of laser trabeculoplasty. Argon laser trabeculoplasty uses a laser to initiate cellular and biochemical changes to the junction of the anterior pigmented and posterior non-pigmented trabecular meshwork, with the power titrated to achieve blanching ADDIN EN.CITE <EndNote><Cite><Author>Sihota</Author><Year>2011</Year><RecNum>811</RecNum><DisplayText>(Sihota 2011)</DisplayText><record><rec-number>811</rec-number><foreign-keys><key app="EN" db-id="wsvssztxiw0dsbeat085zeafe2aa0w0psvpt" timestamp="1488514173">811</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Sihota, R.</author></authors></contributors><auth-address>Glaucoma Research Facility and Clinical Services, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India. rjsihota@</auth-address><titles><title>Lasers in primary open angle glaucoma</title><secondary-title>Indian J Ophthalmol</secondary-title></titles><periodical><full-title>Indian J Ophthalmol</full-title></periodical><pages>S114-7</pages><volume>59 Suppl</volume><edition>2010/12/22</edition><keywords><keyword>Glaucoma, Open-Angle/physiopathology/ surgery</keyword><keyword>Humans</keyword><keyword>Intraocular Pressure</keyword><keyword>Laser Therapy</keyword><keyword>Lasers, Gas/ therapeutic use</keyword><keyword>Ophthalmologic Surgical Procedures/ methods</keyword><keyword>Postoperative Period</keyword><keyword>Sclera/surgery</keyword><keyword>Trabeculectomy</keyword></keywords><dates><year>2011</year><pub-dates><date>Jan</date></pub-dates></dates><isbn>1998-3689 (Electronic)
0301-4738 (Linking)</isbn><accession-num>21150022</accession-num><urls><related-urls><url>;(Sihota 2011). These changes result in increased aqueous humour flow and lower IOP. However, selective laser trabeculoplasty is now more commonly performed in many countries including Australia as the thermally mediated radiation damage caused by the argon laser is confined to the pigmented trabecular meshwork cells, which absorb more of the applied laser energy than the surrounding cells ADDIN EN.CITE <EndNote><Cite><Author>Realini</Author><Year>2008</Year><RecNum>730</RecNum><DisplayText>(Realini 2008)</DisplayText><record><rec-number>730</rec-number><foreign-keys><key app="EN" db-id="wsvssztxiw0dsbeat085zeafe2aa0w0psvpt" timestamp="1488514171">730</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Realini, T.</author></authors></contributors><auth-address>Department of Ophthalmology, West Virginia University, Morgantown, WV 26505, USA. realinia@</auth-address><titles><title>Selective laser trabeculoplasty: a review</title><secondary-title>J Glaucoma</secondary-title></titles><periodical><full-title>J Glaucoma</full-title></periodical><pages>497-502</pages><volume>17</volume><number>6</number><edition>2008/09/17</edition><keywords><keyword>Glaucoma, Open-Angle/physiopathology/ surgery</keyword><keyword>Humans</keyword><keyword>Intraocular Pressure/physiology</keyword><keyword>Lasers, Gas</keyword><keyword>Lasers, Solid-State</keyword><keyword>Trabeculectomy/ methods</keyword></keywords><dates><year>2008</year><pub-dates><date>Sep</date></pub-dates></dates><isbn>1536-481X (Electronic)
1057-0829 (Linking)</isbn><accession-num>18794688</accession-num><urls><related-urls><url>;(Realini 2008). The two laser trabeculoplasty methods are compared in Table 1. According to the National Health and Medical Research Council (NHMRC) Guidelines for the Screening, Prognosis, Diagnosis, Management and Prevention of Glaucoma 2010 ADDIN EN.CITE <EndNote><Cite><Author>NHMRC</Author><Year>2010</Year><RecNum>1084</RecNum><DisplayText>(NHMRC 2010)</DisplayText><record><rec-number>1084</rec-number><foreign-keys><key app="EN" db-id="wsvssztxiw0dsbeat085zeafe2aa0w0psvpt" timestamp="1488781950">1084</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>NHMRC</author></authors><tertiary-authors><author>Australian Governemnt,</author></tertiary-authors></contributors><titles><title>NHMRC Guidelines for the Screening , Prognosis, Diagnosis, Management and Prevention of Glaucoma</title></titles><dates><year>2010</year></dates><urls></urls></record></Cite></EndNote>(NHMRC 2010), the literature reports that argon laser trabeculoplasty and selective laser trabeculoplasty are equally effective in reducing IOP.Table 1Comparison of argon laser trabeculoplasty and selective laser trabeculoplasty surgeries-Argon laser trabeculoplastySelective laser trabeculoplastySpot size50 μm400 μmNo. of spots50 spots equally spaced over 180° of the TM50 spots covering a total of 360° of the TMEnergy used500 mW<1% of ALTFluence40,000 mJ/mm2>0.00015% of ALTExposure time0.1 second3 nanosecondsEffectThermal damageNo thermal damageSource: Sihota ADDIN EN.CITE <EndNote><Cite ExcludeAuth="1"><Author>Sihota</Author><Year>2011</Year><RecNum>811</RecNum><DisplayText>(2011)</DisplayText><record><rec-number>811</rec-number><foreign-keys><key app="EN" db-id="wsvssztxiw0dsbeat085zeafe2aa0w0psvpt" timestamp="1488514173">811</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Sihota, R.</author></authors></contributors><auth-address>Glaucoma Research Facility and Clinical Services, Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India. rjsihota@</auth-address><titles><title>Lasers in primary open angle glaucoma</title><secondary-title>Indian J Ophthalmol</secondary-title></titles><periodical><full-title>Indian J Ophthalmol</full-title></periodical><pages>S114-7</pages><volume>59 Suppl</volume><edition>2010/12/22</edition><keywords><keyword>Glaucoma, Open-Angle/physiopathology/ surgery</keyword><keyword>Humans</keyword><keyword>Intraocular Pressure</keyword><keyword>Laser Therapy</keyword><keyword>Lasers, Gas/ therapeutic use</keyword><keyword>Ophthalmologic Surgical Procedures/ methods</keyword><keyword>Postoperative Period</keyword><keyword>Sclera/surgery</keyword><keyword>Trabeculectomy</keyword></keywords><dates><year>2011</year><pub-dates><date>Jan</date></pub-dates></dates><isbn>1998-3689 (Electronic)
0301-4738 (Linking)</isbn><accession-num>21150022</accession-num><urls><related-urls><url>;(2011)The NHMRC guidelines recommend laser trabeculoplasty for older patients with glaucoma who are at risk of visual loss within their lifetime, particularly when the following factors apply:there is difficulty with administering eye drops;patients are unresponsive to medication alone; or,patients are poor candidates for incisional surgery.The patients in population 2 fall within these parameters.Population 3: Patients with POAG who have no history of cataractsCurrently, patients with no history of cataracts in whom the target IOP is not being achieved and laser trabeculoplasty has failed or is not likely to succeed would be considered for incisional surgical approaches, such as trabeculectomy. MIGS stent implantation is being proposed as an alternative procedure at this stage, trabeculectomy as well as other incisional surgical approaches would be the appropriate comparators to MIGS stent implantation in this population. Incisional filtration surgery, including trabeculectomy, is reimbursed under MBS item numbers 42746 (first surgery) and 42749 (subsequent surgeries).The purpose of surgical treatment for POAG is to prevent glaucoma-induced visual disability. Incisional surgery is often considered a third choice approach after medication and laser therapy due to the risk of damaging the natural lens. Incisional surgical procedures include:Trabeculectomy: Incisional filtering microsurgery that involves surgically creating a drainage channel between the anterior chamber and subconjunctival space. The subconjunctival space consists of loose connective tissue and the surgical dissection and subsequent aqueous flow are believed to stimulate fibrosis in this tissue which reduces the outflow of aqueous over time.If populations 2 and 3 are combined, the applicant has indicated trabeculectomy would be the appropriate comparator for the merged population. The submission-based assessment should be explicit regarding whether laser trabeculoplasty is a prior-treatment, or a possible comparator. Filtrating surgeries, such as deep sclerectomy, viscocanalostomy and canaloplasty:These surgeries are not widely used in Australia. They have common elements involving the dissection of a superficial and deep scleral flap to create an intra-scleral lake, removal of the juxtacanalicular tissue, and a Descemet’s window. They can be performed after a trabeculectomy has failed.Viscocanalostomy involves removal of the inner wall endothelium of Schlemm’s canal as well as the juxtacanalicular tissue, the normal site of outflow resistance and the superficial flap is closed with 10–0 monofilament nylon sutures that are applied loosely.During canaloplasty, the entire circumference of Schlemm’s canal is dilated and extended with a viscoelastic compound, followed by placement of 10/0 polypropylene sutures in the canal under tension.With sclerectomy, the Schlemm's canal was de-roofed and the corneal stroma was excised down to Descemet's membrane so that the aqueous humour percolates through the thin remaining trabeculo-Descemetic membrane. Deep sclerectomy can also be performed with a cylindrical collagen drainage device placed radially in the centre of the deep sclerectomy dissection.Aqueous/tube shunt implantation:Aqueous shunts or tube shunts are devices that create an alternate path for the aqueous humour to leave the anterior chamber of the eye and lower IOP. In general, a tube is implanted into the anterior chamber of the eye that drains through a plate attached to the sclera and is covered by the eyelid. The fluid that collects is then absorbed into the bloodstream and transported out of the eye cavity. This procedure is usually considered a last-line procedure in patients with advanced disease. Therefore, aqueous/tube shunt implantation in unlikely to be an appropriate comparator for MIGS stent implantation in this population. Insertion of aqueous/tube shunts is reimbursed under MBS item numbers 42752 (insertion) and 42755 (removal). RationaleThere are two types of MIGS stent implantation procedure currently being reviewed for MBS funding: trabecular bypass MIGS stent implantation (this application) and suprachoroidal MIGS stent implantation (MBS application 1496). PASC advised that suprachoroidal MIGS should be an additional comparator to trabecular bypass MIGS for all three populations. Additionally, any available data to compare the effectiveness of the three trabecular bypass stents should be included in the report.There are five RCTs investigating effectiveness of combined trabecular bypass MIGS and cataract surgery, compared with cataract surgery alone. There is therefore likely to be sufficient evidence to inform effectiveness of trabecular bypass MIGS in population 1. Lack of evidence for population 2 has already been highlighted.The two RCTs investigating effectiveness of trabecular bypass MIGS in phakic patients (population 3) compared trabecular bypass MIGS with topical hypotensive medication PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GZWE8L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFyPjxSZWNO
dW0+MjM3PC9SZWNOdW0+PERpc3BsYXlUZXh0PihGZWEgZXQgYWwuIDIwMTQ7IFZvbGQgZXQgYWwu
IDIwMTYpPC9EaXNwbGF5VGV4dD48cmVjb3JkPjxyZWMtbnVtYmVyPjIzNzwvcmVjLW51bWJlcj48
Zm9yZWlnbi1rZXlzPjxrZXkgYXBwPSJFTiIgZGItaWQ9IndzdnNzenR4aXcwZHNiZWF0MDg1emVh
ZmUyYWEwdzBwc3ZwdCIgdGltZXN0YW1wPSIxNDg4NTE0MTYzIj4yMzc8L2tleT48L2ZvcmVpZ24t
a2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRy
aWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPkZlYSwgQS4gTS48L2F1dGhvcj48YXV0aG9yPkJlbGRh
LCBKLiBJLjwvYXV0aG9yPjxhdXRob3I+UmVrYXMsIE0uPC9hdXRob3I+PGF1dGhvcj5KdW5lbWFu
biwgQS48L2F1dGhvcj48YXV0aG9yPkNoYW5nLCBMLjwvYXV0aG9yPjxhdXRob3I+UGFibG8sIEwu
PC9hdXRob3I+PGF1dGhvcj5Wb3NrYW55YW4sIEwuPC9hdXRob3I+PGF1dGhvcj5LYXR6LCBMLiBK
LjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPlVuaXZlcnNp
dGEgZGVnbGkgU3R1ZGkgZGkgVG9yaW5vLCBDbGluaWNhIE9jdWxpc3RpY2EsIFRvcmlubywgSXRh
bHkuJiN4RDtIb3NwaXRhbCBUb3JyZXZpZWphIFNhbHVkLCBVVEUsIFNlcnZpY2lvIGRlIE9mdGFs
bW9sb2dpYSwgQWxpY2FudGUsIFNwYWluLiYjeEQ7TWlsaXRhcnkgSW5zdGl0dXRlIG9mIE1lZGlj
aW5lLCBEZXBhcnRtZW50IG9mIE9waHRoYWxtb2xvZ3ksIFdhcnNhdywgUG9sYW5kLiYjeEQ7VW5p
dmVyc2l0YXRzYXVnZW5rbGluaWssIEVybGFuZ2VuLCBHZXJtYW55LiYjeEQ7SGluY2hpbmdicm9v
a2UgSG9zcGl0YWwgTkhTIFRydXN0IGFuZCBNb29yZmllbGRzIEJlZGZvcmQgSG9zcGl0YWwgTkhT
IFRydXN0LCBVbml0ZWQgS2luZ2RvbS4mI3hEO0hvc3BpdGFsIFVuaXZlcnNpdGFyaW8gTWlndWVs
IFNlcnZldCwgU2VydmljaW8gT2Z0YWxtb2xvZ2ljbywgWmFyYWdvemEsIFNwYWluLiYjeEQ7U1Yg
TWFsYXlhbiBPcGh0aGFsbW9sb2dpY2FsIENlbnRlciwgWWVyZXZhbiwgQXJtZW5pYS4mI3hEO1dp
bGxzIEV5ZSBJbnN0aXR1dGUsIEplZmZlcnNvbiBNZWRpY2FsIENvbGxlZ2UsIFBoaWxhZGVscGhp
YSwgUEEsIFVTQS48L2F1dGgtYWRkcmVzcz48dGl0bGVzPjx0aXRsZT5Qcm9zcGVjdGl2ZSB1bm1h
c2tlZCByYW5kb21pemVkIGV2YWx1YXRpb24gb2YgdGhlIGlTdGVudCBpbmplY3QgKChSKSkgdmVy
c3VzIHR3byBvY3VsYXIgaHlwb3RlbnNpdmUgYWdlbnRzIGluIHBhdGllbnRzIHdpdGggcHJpbWFy
eSBvcGVuLWFuZ2xlIGdsYXVjb21hPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPkNsaW4gT3BodGhh
bG1vbDwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkNs
aW4gT3BodGhhbG1vbDwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjg3NS04MjwvcGFn
ZXM+PHZvbHVtZT44PC92b2x1bWU+PGVkaXRpb24+MjAxNC8wNS8yNDwvZWRpdGlvbj48a2V5d29y
ZHM+PGtleXdvcmQ+SU9QIHJlZHVjdGlvbjwva2V5d29yZD48a2V5d29yZD5PYWc8L2tleXdvcmQ+
PGtleXdvcmQ+YWIgaW50ZXJubzwva2V5d29yZD48a2V5d29yZD5pbnRyYW9jdWxhciBwcmVzc3Vy
ZTwva2V5d29yZD48a2V5d29yZD50cmFiZWN1bGFyIGJ5cGFzczwva2V5d29yZD48L2tleXdvcmRz
PjxkYXRlcz48eWVhcj4yMDE0PC95ZWFyPjwvZGF0ZXM+PGlzYm4+MTE3Ny01NDY3IChQcmludCkm
I3hEOzExNzctNTQ2NyAoTGlua2luZyk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+MjQ4NTUzMzY8L2Fj
Y2Vzc2lvbi1udW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3LmRvdmVwcmVz
cy5jb20vZ2V0ZmlsZS5waHA/ZmlsZUlEPTE5OTEzPC91cmw+PC9yZWxhdGVkLXVybHM+PC91cmxz
PjxjdXN0b20yPlBNQzQwMTk2Mjg8L2N1c3RvbTI+PGVsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjEw
LjIxNDcvb3B0aC5zNTk5MzI8L2VsZWN0cm9uaWMtcmVzb3VyY2UtbnVtPjxyZW1vdGUtZGF0YWJh
c2UtcHJvdmlkZXI+TkxNPC9yZW1vdGUtZGF0YWJhc2UtcHJvdmlkZXI+PGxhbmd1YWdlPmVuZzwv
bGFuZ3VhZ2U+PC9yZWNvcmQ+PC9DaXRlPjxDaXRlPjxBdXRob3I+Vm9sZDwvQXV0aG9yPjxZZWFy
PjIwMTY8L1llYXI+PFJlY051bT4xNjwvUmVjTnVtPjxyZWNvcmQ+PHJlYy1udW1iZXI+MTY8L3Jl
Yy1udW1iZXI+PGZvcmVpZ24ta2V5cz48a2V5IGFwcD0iRU4iIGRiLWlkPSJ3c3Zzc3p0eGl3MGRz
YmVhdDA4NXplYWZlMmFhMHcwcHN2cHQiIHRpbWVzdGFtcD0iMTQ4ODQzMDU3MiI+MTY8L2tleT48
L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRpY2xlIj4xNzwvcmVmLXR5
cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlZvbGQsIFMuIEQuPC9hdXRob3I+PGF1
dGhvcj5Wb3NrYW55YW4sIEwuPC9hdXRob3I+PGF1dGhvcj5UZXR6LCBNLjwvYXV0aG9yPjxhdXRo
b3I+QXVmZmFydGgsIEcuPC9hdXRob3I+PGF1dGhvcj5NYXNvb2QsIEkuPC9hdXRob3I+PGF1dGhv
cj5BdSwgTC48L2F1dGhvcj48YXV0aG9yPkFobWVkLCwgSUk8L2F1dGhvcj48YXV0aG9yPlNhaGVi
LCBILjwvYXV0aG9yPjwvYXV0aG9ycz48L2NvbnRyaWJ1dG9ycz48YXV0aC1hZGRyZXNzPlZvbGQg
VmlzaW9uLCBQTExDLCBGYXlldHRldmlsbGUsIEFSLCBVU0EuIHN2b2xkQHZvbGR2aXNpb24uY29t
LiYjeEQ7Uy5WLiBNYWxheWFuIE9waHRoYWxtb2xvZ3kgQ2VudHJlLCBZZXJldmFuLCBBcm1lbmlh
LiYjeEQ7QmVybGluIEV5ZSBSZXNlYXJjaCBJbnN0aXR1dGUgYW5kIEF1Z2Vua2xpbmlrIFNwcmVl
Ym9nZW4sIEJlcmxpbiwgR2VybWFueS4mI3hEO1VuaXZlcnNpdHkgSG9zcGl0YWwgSGVpZGVsYmVy
ZywgSGVpZGVsYmVyZywgR2VybWFueS4mI3hEO0Jpcm1pbmdoYW0gQ2l0eSBIb3NwaXRhbCwgQmly
bWluZ2hhbSwgVUsuJiN4RDtNYW5jaGVzdGVyIFJveWFsIEV5ZSBIb3NwaXRhbCwgTWFuY2hlc3Rl
ciwgVUsuJiN4RDtVbml2ZXJzaXR5IG9mIFRvcm9udG8sIFRvcm9udG8sIE9OLCBDYW5hZGEuJiN4
RDtNY0dpbGwgVW5pdmVyc2l0eSwgTW9udHJlYWwsIFFDLCBDYW5hZGEuPC9hdXRoLWFkZHJlc3M+
PHRpdGxlcz48dGl0bGU+TmV3bHkgRGlhZ25vc2VkIFByaW1hcnkgT3Blbi1BbmdsZSBHbGF1Y29t
YSBSYW5kb21pemVkIHRvIDIgVHJhYmVjdWxhciBCeXBhc3MgU3RlbnRzIG9yIFByb3N0YWdsYW5k
aW46IE91dGNvbWVzIFRocm91Z2ggMzYgTW9udGhzPC90aXRsZT48c2Vjb25kYXJ5LXRpdGxlPk9w
aHRoYWxtb2wgVGhlcjwvc2Vjb25kYXJ5LXRpdGxlPjwvdGl0bGVzPjxwZXJpb2RpY2FsPjxmdWxs
LXRpdGxlPk9waHRoYWxtb2wgVGhlcjwvZnVsbC10aXRsZT48L3BlcmlvZGljYWw+PHBhZ2VzPjE2
MS0xNzI8L3BhZ2VzPjx2b2x1bWU+NTwvdm9sdW1lPjxudW1iZXI+MjwvbnVtYmVyPjxlZGl0aW9u
PjIwMTYvMTEvMDU8L2VkaXRpb24+PGtleXdvcmRzPjxrZXl3b3JkPkdsYXVjb21hPC9rZXl3b3Jk
PjxrZXl3b3JkPklvcDwva2V5d29yZD48a2V5d29yZD5NaWdzPC9rZXl3b3JkPjxrZXl3b3JkPlBv
YWc8L2tleXdvcmQ+PGtleXdvcmQ+UHJvc3RhZ2xhbmRpbjwva2V5d29yZD48a2V5d29yZD5UcmFi
ZWN1bGFyIGJ5cGFzczwva2V5d29yZD48L2tleXdvcmRzPjxkYXRlcz48eWVhcj4yMDE2PC95ZWFy
PjxwdWItZGF0ZXM+PGRhdGU+RGVjPC9kYXRlPjwvcHViLWRhdGVzPjwvZGF0ZXM+PGlzYm4+MjE5
My04MjQ1IChQcmludCk8L2lzYm4+PGFjY2Vzc2lvbi1udW0+Mjc2MTkyMjU8L2FjY2Vzc2lvbi1u
dW0+PHVybHM+PHJlbGF0ZWQtdXJscz48dXJsPmh0dHBzOi8vd3d3Lm5jYmkubmxtLm5paC5nb3Yv
cG1jL2FydGljbGVzL1BNQzUxMjUxMjYvcGRmLzQwMTIzXzIwMTZfQXJ0aWNsZV82NS5wZGY8L3Vy
bD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGN1c3RvbTI+UE1DNTEyNTEyNjwvY3VzdG9tMj48ZWxl
Y3Ryb25pYy1yZXNvdXJjZS1udW0+MTAuMTAwNy9zNDAxMjMtMDE2LTAwNjUtMzwvZWxlY3Ryb25p
Yy1yZXNvdXJjZS1udW0+PHJlbW90ZS1kYXRhYmFzZS1wcm92aWRlcj5OTE08L3JlbW90ZS1kYXRh
YmFzZS1wcm92aWRlcj48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48L3JlY29yZD48L0NpdGU+PC9F
bmROb3RlPgB=
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5GZWE8L0F1dGhvcj48WWVhcj4yMDE0PC9ZZWFyPjxSZWNO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ADDIN EN.CITE.DATA (Fea et al. 2014; Vold et al. 2016). This comparator is inappropriate for this population, based on the clinical algorithm. Thus, the effectiveness of trabecular bypass MIGS may need to be assessed using indirect evidence. OutcomesPatient relevant outcomesClinical Effectiveness:Rate of vision impairment/loss, proportion of vision impairment/loss, time to vision impairment/loss, mean IOP reduction from baseline, proportion of patients with IOP reduction ≥ 20%, proportion of patients with IOP ≤ 18 mmHg, time to increase in IOP, change in the number of ocular hypotensive medications, proportion of patients on medication quality of life (effect on daily living activities, e.g. driving, walking, and reading), health-related quality of life (psychological burden due to fear of blindness, social withdrawal, and depression).Safety:Intraoperative complications, post-operative ocular complications, secondary surgical interventions, corrected distance visual acuity, visual field mean deviation.Healthcare systemCost-effectivenessCost, cost per quality adjusted life year or disability adjusted life year, incremental cost-effectiveness ratio.Financial implicationsNumber of patients suitable for treatment, number of patients who have successful procedure, number of patients who require additional treatment (medical or surgical).Clinical management algorithm with and without MIGS stent implantation for the identified populationsThe clinical management algorithm for patients with suspected POAG, showing treatment options with and without MIGS stent implantation for patients with mild disease through progression to advanced disease are shown in Figure 1. The algorithm was adapted from the NHMRC Guidelines for the screening, prognosis, diagnosis, management and prevention of glaucoma ADDIN EN.CITE <EndNote><Cite><Author>NHMRC</Author><Year>2010</Year><RecNum>1084</RecNum><DisplayText>(NHMRC 2010)</DisplayText><record><rec-number>1084</rec-number><foreign-keys><key app="EN" db-id="wsvssztxiw0dsbeat085zeafe2aa0w0psvpt" timestamp="1488781950">1084</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>NHMRC</author></authors><tertiary-authors><author>Australian Governemnt,</author></tertiary-authors></contributors><titles><title>NHMRC Guidelines for the Screening , Prognosis, Diagnosis, Management and Prevention of Glaucoma</title></titles><dates><year>2010</year></dates><urls></urls></record></Cite></EndNote>(NHMRC 2010).The objective of glaucoma management is to provide a significant and sustained decrease in lOP to minimise the risk of progression (i.e. visual field loss), which impacts on the patient's QoL. For the majority of POAG patients, topical hypotensive medication represents the first-line of therapy as they represent the least invasive treatment option. Patients will initiate with a single topical medication, and the dosing frequency and number of therapies will increase, as required, in order to maintain a target IOP. In patients with cataracts requiring surgery, concurrent MIGS stent implantation (either suprachoroidal or trabecular bypass) offers another option for lowering IOP.As the condition progresses, hypotensive medication may become less efficacious, or patients may become non-compliant. For such patients, surgical treatment options are considered. Laser trabeculoplasty is usually considered as the first procedure in patients where IOP cannot be adequately managed with medication alone. MIGS stent implantation is also considered to be an alternative treatment for patients who have had previous cataract surgery at this stage. As the natural lens takes up more space in the eye, there is a risk that surgical procedures may damage the natural lens. As there is no such risk in pseudophakic patients who have had cataract surgery, MIGS is a viable alternative to laser trabeculoplasty.Following laser trabeculoplasty, more invasive surgical treatment options, known broadly as ‘filtering’ surgeries, may be considered. The most common first invasive procedure is trabeculectomy. In phakic patients who have no history of cataracts and still have their natural lens, MIGS stent implantation is considered to be a viable alternative option at this stage. In these patents trabeculectomy could still be performed after the MIGS stent implant has failed.Sclerectomy, viscocanalostomy and canaloplasty are not widely used in Australia but may offer further options to patients in whom all previous treatments have failed. The last line of treatment is aqueous/tube shunt implantation. These surgeries are generally reserved for patients with advanced disease. In combining populations 2 and 3 in the assessment, the appropriate clinical management algorithm (for the combined population) will be that shown for population 2 in Figure 1 (if ‘conservative therapies’ exclude laser trabeculoplasty), or population 3 if it includes laser trabeculoplasty.Figure 1The clinical management algorithm for patients with POAG, showing treatment options with and without trabecular bypass MIGS stent implantation for patients with mild to moderate disease through progression to advanced diseaseSource: NHMRC Guidelines: For the screening, prognosis, diagnosis, management and prevention of glaucoma ADDIN EN.CITE <EndNote><Cite><Author>NHMRC</Author><Year>2010</Year><RecNum>1084</RecNum><DisplayText>(NHMRC 2010)</DisplayText><record><rec-number>1084</rec-number><foreign-keys><key app="EN" db-id="wsvssztxiw0dsbeat085zeafe2aa0w0psvpt" timestamp="1488781950">1084</key></foreign-keys><ref-type name="Report">27</ref-type><contributors><authors><author>NHMRC</author></authors><tertiary-authors><author>Australian Governemnt,</author></tertiary-authors></contributors><titles><title>NHMRC Guidelines for the Screening , Prognosis, Diagnosis, Management and Prevention of Glaucoma</title></titles><dates><year>2010</year></dates><urls></urls></record></Cite></EndNote>(NHMRC 2010)The addition of trabecular bypass MIGS as a treatment option is shown in red for all three populationsIOP = intraocular pressure; MIGS = micro-invasive glaucoma surgery; POAG = primary open-angle glaucomaProposed economic evaluationThe applicant has predicted a claim of superiority for comparative effectiveness, and inferiority for comparative safety, for trabecular bypass MIGS plus cataract surgery (compared with cataract surgery alone) in population 1. The applicant has also predicted a claim of at least non-inferiority in terms of comparative clinical effectiveness and safety for trabecular bypass MIGS (plus standard of care), compared with laser trabeculoplasty (plus standard of care) in population 2. The predicted claim for population 3 is for inferior comparative effectiveness and superior comparative safety of trabecular bypass MIGS over trabeculectomy. On the basis of these claims, PASC advised the appropriate type of economic evaluation would be either a cost-effectiveness or cost-utility analysis.PASC considered that a comparison between the three different trabecular bypass MIGS stents, and between the trabecular bypass and suprachoroidal MIGS stent implantation procedures, be included in the submission-based assessment.. If the evidence suggests the different types of MIGS stents are equivalent, a cost-minimisation approach would be appropriate. The Technical Guidelines for preparing assessment reports for the Medical Services Advisory Committee outline how to structure the decision analytic model underpinning the proposed economic evaluation, which is informed by the final structure of the PICO agreed to by PASC.Proposed item descriptorTrabecular bypass MIGS stent implantation has been performed in Australia for the last 3–4 years and has been funded under MBS item number 42758 (goniotomy). However, an MBS review determined that item 42758 was never intended to cover implantation of MIGS stents, and an amendment explicitly excluding this procedure was included in the item from 1 May 2017. This MSAC application is seeking a new MBS item for delivery of trabecular bypass MIGS stent devices in the nominated patient populations (Table 2). The cost of micro-bypass stent prostheses is not included in the MBS fee. Prostheses are funded through the Prostheses List.The implantation procedure would be performed once per eye (maximum two procedures per patient), as the stents are designed to last a lifetime. However, they may need repositioning or removal at a later date.Differences in duration and complexity of the procedure when performed as a ‘stand-alone procedure’ (compared to being performed ‘in conjunction with cataract surgery’) needs clarification and the costs justified. These procedures may require separate MBS item numbers, if costs vary.The applicant advised that the total service fee must account for other aspects of the procedure (broader than the surgeon’s time), such as preparation time, clinic overheads, observation and post-operative recovery time. There is an economy of scale in performing MIGS implantation in conjunction with cataract surgery, which is recognised by application of the MBS Multiple Services Rule.The proposed MBS fee for repositioning and removal of the stent is the same as for its insertion, and PASC considered that this needs justification.Potential for leakage should also be addressed. PASC noted the concern that, given only 20% of patients with cataracts have increased IOP, MIGS may be performed prophylactically in patients requiring cataract surgery. Therefore, the risk that more procedures may be performed than actually required, needs to be considred.The three trabecular bypass MIGS stent devices that are relevant to the treatment of patients with mild-to-moderate POAG, with or without cataracts, are listed on the Prostheses List (Billing codes: iStent trabecular micro-bypass stent system RQ072, iStent inject system RQ075, Hydrus microstent OQ002). Prostheses List benefits for glaucoma drainage devices range from $800 to $1,600 each. PASC recommended that the difference between usage of these devices (and their impact on the treatment populations) be investigated further.Table 2MBS item descriptors for trabecular bypass MIGS stent implantationCategory 3 – THERAPEUTIC PROCEDURESMBS item numberGLAUCOMA, implantation of a micro-invasive glaucoma surgery stent system into the trabecular meshwork, in patients diagnosed with primary open-angle glaucoma currently treated with ocular hypotensive medication.Can be delivered as a stand-alone procedure or in conjunction with cataract surgery.When delivered as a stand-alone procedure, pseudophakic patients must have inadequate IOP control with maximally-tolerated ocular hypotensive medication, and phakic patients must have failed or be likely to fail laser trabeculoplasty, or be contraindicated for this procedureMultiple Services RuleFee: $699.45 [approximate fee based on MBS item 42758 – to be determined]MBS item numberGLAUCOMA, repositioning or removal of, a micro-invasive glaucoma surgery stent system from the trabecular meshworkMultiple Services RuleFee: $699.45 [approximate fee based on MBS item 42758 – to be determined]The MBS item descriptor for filtering surgeries restricts the intervention to glaucoma patients “where conservative therapies have failed, are likely to fail, or are contraindicated”. If populations 2 and 3 are combined, the patient population likely to access stand-alone MIGS stent implantation through the MBS are those otherwise eligible for incisional filtering surgeries. Thus, the wording for the proposed MBS item descriptor could be amended to read: “When delivered as a stand-alone procedure, conservative therapies must have failed, be likely to fail, or be contraindicated”The applicant has indicated that a comprehensive cost analysis of the proposed service will be undertaken during development of the submission based assessment and that the fee would be expected to be similar to the current fee for MBS item number 42758 (goniotomy). Advice from the Royal Australian and New Zealand College of Ophthalmologists (RANZCO) suggests the fee for this service ($699.45, as for goniotomy) is a reasonable representation of the true cost of delivering the proposed service. A response to a targeted consultation survey on MSAC Application 1483 indicated the proposed service should be rebated at a rate comparable to goniotomy (MBS item number 42758).A second response to the consultation survey indicated the proposed fee is possibly higher than the procedure warrants, whereas the Australian and New Zealand Glaucoma Society (ANZGS) stated the proposed fee is already lower than in other developed countries for insertion of the trabecular device. References ADDIN EN.REFLIST Allingham, RR, Liu, Y & Rhee, DJ 2009, 'The genetics of primary open-angle glaucoma: a review', Exp Eye Res, vol. 88, no. 4, pp. 837-844.Boland, MV, Ervin, AM, Friedman, DS, Jampel, HD, Hawkins, BS, Vollenweider, D, Chelladurai, Y, Ward, D, Suarez-Cuervo, C & Robinson, KA 2013, 'Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force', Ann Intern Med, vol. 158, no. 4, pp. 271-279.Conlon, R, Saheb, H & Ahmed, II 2017, 'Glaucoma treatment trends: a review', Can J Ophthalmol, vol. 52, no. 1, pp. 114-124.Fea, AM, Belda, JI, Rekas, M, Junemann, A, Chang, L, Pablo, L, Voskanyan, L & Katz, LJ 2014, 'Prospective unmasked randomized evaluation of the iStent inject ((R)) versus two ocular hypotensive agents in patients with primary open-angle glaucoma', Clin Ophthalmol, vol. 8, pp. 875-882.Foster, PJ, Buhrmann, R, Quigley, HA & Johnson, GJ 2002, 'The definition and classification of glaucoma in prevalence surveys', British Journal of Ophthalmology, vol. 86, no. 2, pp. 238-242.Gallardo, MJ, Supnet, RA, Giamporcaro, JE & Hornbeak, DM 2016, 'Outcomes of combined trabecular micro-bypass and phacoemulsification in a predominantly Hispanic patient population', Clin Ophthalmol, vol. 10, pp. 1931-1937.Gonnermann, J, Bertelmann, E, Pahlitzsch, M, Maier-Wenzel, AB, Torun, N & Klamann, MK 2017, 'Contralateral eye comparison study in MICS & MIGS: Trabectome(R) vs. iStent inject(R)', Graefes Arch Clin Exp Ophthalmol, vol. 255, no. 2, pp. 359-365.Janssen, SF, Gorgels, TG, Ramdas, WD, Klaver, CC, van Duijn, CM, Jansonius, NM & Bergen, AA 2013, 'The vast complexity of primary open angle glaucoma: disease genes, risks, molecular mechanisms and pathobiology', Prog Retin Eye Res, vol. 37, pp. 31-67.Katz, LJ, Erb, C, Carceller, GA, Fea, AM, Voskanyan, L, Wells, JM & Giamporcaro, JE 2015, 'Prospective, randomized study of one, two, or three trabecular bypass stents in open-angle glaucoma subjects on topical hypotensive medication', Clin Ophthalmol, vol. 9, pp. 2313-2320.Kwon, YH, Fingert, JH, Kuehn, MH & Alward, WL 2009, 'Primary open-angle glaucoma', N Engl J Med, vol. 360, no. 11, pp. 1113-1124.Leske, MC 1983, 'The Epidemiology of Open-Angle Glaucoma: A Review', American Journal of Epidemiology, vol. 118, no. 2, pp. 166-191.Lindstrom, R, Lewis, R, Hornbeak, DM, Voskanyan, L, Giamporcaro, JE, Hovanesian, J & Sarkisian, S 2016, 'Outcomes Following Implantation of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with Open-Angle Glaucoma on One Medication: 18-Month Follow-Up', Adv Ther, vol. 33, no. 11, pp. 2082-2090.Maier, PC, Funk, J, Schwarzer, G, Antes, G & Falck-Ytter, YT 2005, 'Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials', BMJ, vol. 331, no. 7509, p. 134.Neuhann, TH 2015, 'Trabecular micro-bypass stent implantation during small-incision cataract surgery for open-angle glaucoma or ocular hypertension: Long-term results', J Cataract Refract Surg, vol. 41, no. 12, pp. 2664-2671.NHMRC 2010, NHMRC Guidelines for the Screening , Prognosis, Diagnosis, Management and Prevention of Glaucoma.Peters, D, Bengtsson, B & Heijl, A 2013, 'Lifetime risk of blindness in open-angle glaucoma', Am J Ophthalmol, vol. 156, no. 4, pp. 724-730.Quigley, HA 2011, 'Glaucoma', Lancet, vol. 377, no. 9774, pp. 1367-1377.Realini, T 2008, 'Selective laser trabeculoplasty: a review', J Glaucoma, vol. 17, no. 6, pp. 497-502.Sihota, R 2011, 'Lasers in primary open angle glaucoma', Indian J Ophthalmol, vol. 59 Suppl, pp. S114-117.Vold, SD, Voskanyan, L, Tetz, M, Auffarth, G, Masood, I, Au, L, Ahmed, II & Saheb, H 2016, 'Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months', Ophthalmol Ther, vol. 5, no. 2, pp. 161-172. ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
Related searches
- nevada department of health license
- colorado department of health and human services
- nevada department of health licensing
- ny state department of health forms
- department of health certification illinois
- nys department of health license verifica
- new york department of health license lookup
- bergen county department of health services
- tennessee department of health license renewal
- department of health jobs pa
- colorado department of health and environment
- tn department of health licensure